|
Tumor Progression
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Correction: Expression of MYSM1 is associated with tumor progression in colorectal cancer.
|
29020094 |
2017 |
|
Tumor Progression
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Expression of MYSM1 is associated with tumor progression in colorectal cancer.
|
28498834 |
2017 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Scratch assay and Transwell assay showed that MYSM1 silencing decreased migration and invasion abilities of SW480 cells.
|
28498834 |
2017 |
|
Rhizomelia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Renal fibrosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our results are clearly indicating that, aspirin prevents renal fibrosis in diabetic animals through decreasing the expression of Mysm1, increasing the expression of H2AK119-Ub and thereby decreasing the protein expression of Set7, which is a novel mechanism.
|
29656179 |
2018 |
|
Recurrent respiratory infections
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Prostatic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We observed that MYSM1 were downregulated in CRPC compared to localized prostate tumors.
|
31761786 |
2019 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Integrative bioinformatic analyses of the significantly associated genes with MYSM1 revealed MYSM1-correlated pathways, providing substantial clues as to the role of MYSM1 in PCa.
|
31761786 |
2019 |
|
Primary immune deficiency disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
We report a case of NP associated with myelodysplasia in a child with MYSM1 deficiency, a newly described syndrome with primary immunodeficiency (PI), bone marrow failure, and developmental aberrations.
|
30746751 |
2019 |
|
Pancytopenia
|
0.310 |
Biomarker
|
disease |
BEFREE |
Myb-like, SWIRM, and MPN domains 1 (MYSM1) deficiency: Genotoxic stress-associated bone marrow failure and developmental aberrations.
|
28115216 |
2017 |
|
Pancytopenia
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes.
|
26474655 |
2015 |
|
Osteopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In summary, our results demonstrate novel roles for Mysm1 in osteoblast differentiation and osteoclast formation, resulting in osteopenia in Mysm1-deficient mice that could be abrogated by the loss of p53 from increased osteogenic differentiation of Mysm1<sup>-/-</sup>p53<sup>-/-</sup> MSCs.-Haffner-Luntzer, M., Kovtun, A., Fischer, V., Prystaz, K., Hainzl, A., Kroeger, C. M., Krikki, I., Brinker, T. J., Ignatius, A., Gatzka, M. Loss of p53 compensates osteopenia in murine Mysm1 deficiency.
|
29203593 |
2018 |
|
Neutrophilic panniculitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We report a case of NP associated with myelodysplasia in a child with MYSM1 deficiency, a newly described syndrome with primary immunodeficiency (PI), bone marrow failure, and developmental aberrations.
|
30746751 |
2019 |
|
Neurodevelopmental delay
|
0.300 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes.
|
26474655 |
2015 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Mysm1-deficient ASCs exacerbated inflammatory bowel diseases but inhibited tumour growth in vivo.
|
30895711 |
2019 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Patients with positiveMYSM1expression showed poor survival compared with the MYSM1 negative group (P<0.001).Simultaneously, multivariate Cox regression analysis indicated thatMYSM1 expression in tumor cells was an independent factor for reduced overall survival in CRC patients (P<0.001).Additionally,MYSM1 in CRC SW480 cells was silenced by small interference RNA (siRNA) technology.
|
28498834 |
2017 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In context with our finding that MYSM1 bound to the <i>c-MET</i> promoter region in close vicinity to PAX3 in melanoma cells, our data indicate that MYSM1 is an epigenetic regulator of melanoma growth and potentially promising new target for tumor therapy.
|
28978033 |
2017 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Correlation analyses by Pearson's chi-square test demonstrated that MYSM1 in tumors was positively correlated with tumor status (pathological assessment of the primary tumor (pT, P<0.001), regional lymph nodes (pN, P = 0.013), distant metastasis (pM, P<0.001)) and clinic stage (P<0.001); Whereas, MYSM1 was not associated with tumor size of CRC patients and was positively associated with tumor differentiation grade (P = 0.015).
|
28498834 |
2017 |
|
MYELODYSPLASTIC SYNDROME
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We report a case of NP associated with myelodysplasia in a child with MYSM1 deficiency, a newly described syndrome with primary immunodeficiency (PI), bone marrow failure, and developmental aberrations.
|
30746751 |
2019 |
|
Myelodysplasia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We report a case of NP associated with myelodysplasia in a child with MYSM1 deficiency, a newly described syndrome with primary immunodeficiency (PI), bone marrow failure, and developmental aberrations.
|
30746751 |
2019 |
|
Midface retrusion
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In context with our finding that MYSM1 bound to the <i>c-MET</i> promoter region in close vicinity to PAX3 in melanoma cells, our data indicate that MYSM1 is an epigenetic regulator of melanoma growth and potentially promising new target for tumor therapy.
|
28978033 |
2017 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Integrative bioinformatic analyses of the significantly associated genes with MYSM1 revealed MYSM1-correlated pathways, providing substantial clues as to the role of MYSM1 in PCa.
|
31761786 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Expression of MYSM1 is associated with tumor progression in colorectal cancer.
|
28498834 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Correction: Expression of MYSM1 is associated with tumor progression in colorectal cancer.
|
29020094 |
2017 |